European Archives - Page 31 of 1323 - European Medical Journal

AI-BUS: AI Bowel Ultrasound System

Inflammatory bowel disease requires close monitoring to detect flare-ups early and guide treatment.1,2 While endoscopy is the gold…

EMJ Gastroenterology 14.1 2025

Inside, you will find an array of content, including our comprehensive review of the United European Gastroenterology (UEG) Week 2025…

The Irish Experience in Gastric Cancer Prevention: Interim Results

Europe’s Beating Cancer Plan calls for the development of a gastric cancer screening strategy in Europe. The TOwards GAstric cancer…

What’s New in Ulcerative Colitis?

AT THE 2025 United European Gastroenterology (UEG) Week held in Berlin, Germany, an informative session explored emerging approaches for…

Association Between Ultra-Processed Food Consumption and Depression in Adults

Depression, also known as major depressive disorder (MDD), is marked by a loss of interest or pleasure in activities and persistent…

Microbiome Modulation: Translating Function into Clinical Practice

AN ENLIGHTENING session delivered at the annual United European Gastroenterology (UEG) Week 2025, held in Berlin, Germany, brought…

UEG Week 2025 Abstract Highlights

The following highlights spotlight the latest advances in gastroenterology, featuring studies and insights presented at this year’s UEG Week 2025.

UEG 2025 Interview: Jörn Schattenberg

It’s an exciting time for metabolic dysfunction-associated steatotic liver disease (MASLD). It’s one of the key drivers of end-stage liver…

Fast Five: Barbara Schmalfeldt on Gynaecological Cancer Updates

In this episode, Barbara Schmalfeldt highlights the major updates in gynaecological cancers presented at ESMO 2025.

Semaglutide Reduces Liver Fibrosis and Resolves MASH - EMJ

Semaglutide Reduces Liver Fibrosis and Resolves MASH

Semaglutide 2.4 mg/week reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits.